普雷尼蒂克斯全球公司于2月18日发布了2026年第一季度的财报,预计每股亏损0.49美元,收入为3615万美元. Prenetics Global reports Q1 2026 earnings Feb. 18, expected to show a $0.49 loss per share and $36.15M revenue.

预测全球公司(PRE)将于2026年2月18日报告季度收入,分析人员预计每股损失0.49美元,收入3 615万美元。 Prenetics Global (PRE) is set to report quarterly earnings on February 18, 2026, with analysts expecting a loss of $0.49 per share and revenue of $36.15 million. 股票交易额为21.97美元,市场上限为3.6976亿美元,P/E的负比率为10.82。 The stock, trading at $21.97, has a market cap of $369.76 million and a negative P/E ratio of -10.82. 短期利息在1月下跌51.8%,机构投资者持有25.01%的股份。 Short interest dropped 51.8% in January, and institutional investors hold 25.01% of shares. 该公司提供全球遗传和传染病检测,具有协商一致的“稳住”评级和34.00美元目标价格。 The company, which offers genetic and infectious disease testing globally, has a consensus "Hold" rating and a $34.00 target price.